- Alopecia Areata
- Androgenic Alopecia
- Traction Alopecia
- Others
Alopecia Treatment Market size was valued at USD 8.6 billion in 2023 and is poised to grow at a CAGR of 11.2% from 2024 to 2030. Alopecia is an autoimmune disorder in which hair loss and baldness have been observed in both males and females. Various drugs and treatments are marketed such as hair transplant, scalp reduction, and others that prevent alopecia, the incidence of alopecia has increased by 49.2% globally which is higher in the 20-24- and 30-34-years age group for males and females. The change in lifestyle along with rising stress levels and unbalanced diets are the major causes of hair fall which influence the alopecia treatment market demand.
In addition, the increasing geriatric population and hormonal changes cause alopecia which drives the alopecia treatment market growth. The market for alopecia treatment is filled with local and international key players. The increase in research and development activities accelerates the market, The increasing prevalence of Type 1 diabetes, thyroid illness, and multiple sclerosis linked with genetic disorders causes hair fall issues which creates numerous opportunities in the alopecia treatment market. The cost of treatment involves high medications and artificial hair transplants are expensive, also strict regulations policies regarding medications and lack of awareness among people restrain the market growth.
Alopecia Treatment Market Key Developments:
- In June 2022, FDA Approves Eli Lilly and Incyte's OLUMIANT® (baricitinib) As the First and Only Systemic Medicine for Adults with Severe Alopecia Areata treatment.
- In August 2021, Pfizer Inc. announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata. Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 percent scalp hair loss after six months of treatment versus placebo.
Global Alopecia Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
11.2%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Alopecia Treatment Market Dynamics
The increasing prevalence of autoimmune disorders across the world is the major market driver in the Alopecia Treatment Market during the forecast period. The autoimmune disorder is caused due to unhealthy diet and improper lifestyle, 60% of the population suffers from thin hair, with pattern hair loss in both males and females which demands effective treatment options to prevent alopecia. In addition, increasing spending on healthcare infrastructure accelerates the development of treatment options and raises awareness about hair regrowth and treatment alternatives. The genetic factor is directly involved in hair fall, the person suffers from type 1 diabetes, and hypertension is linked with the patient or family. Hence, this will drive the global market growth at a significant rate.
North-America Got Significant Share of
Alopecia Treatment Market Regional Analysis
Based on regions, the market share is segmented into North America, Asia-pacific, Europe, the Middle East, and the African region. The Alopecia Treatment Market in the Asia Pacific hold a significant revenue share in 2022, and, in the following years, it is predicted to increase rapidly. It is attributed to the increasing number of genetic disorders and easy availability of over-the-counter (OTC) drugs, along with the presence of local key players providing herbal and synthetic medications for hair fall treatment, development of well-developed healthcare infrastructure accelerates the market growth in the region. North America is holding the major market share in the global market due to the increasing prevalence of autoimmune disorders along with numerous availabilities of alternatives for the treatment of alopecia, high spending on healthcare will further enhance the market growth and is expected to dominate the market in the upcoming years due to global key players in this region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Alopecia Treatment Market Segmentation
By Disease Treatment
By Drug Class
- Corticosteroids
- 5AR Inhibitors
- Vasodilators
- Others
By End User
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa (MEA)
Frequently Asked Questions
The alopecia treatment market size was valued at usd 8.6 billion in 2023
The alopecia treatment market is poised to grow at a significant cagr of 11.2% from 2023 to 2029.
The leading players in the alopecia treatment market are Johnson & Johnson Services, Inc., Merck & Co. Inc., Cipla Limited, Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc., Aurobindo Pharma, and Mylan N.V. (Viatris Inc.)
Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation, and Seven years forecast is presented from 2024 – 2030
| 1.Executive Summary |
| 2.Global Alopecia Treatment Market Introduction |
| 2.1.Global Alopecia Treatment Market - Taxonomy |
| 2.2.Global Alopecia Treatment Market - Definitions |
| 2.2.1.Cell Type |
| 2.2.2.Drug Class |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Alopecia Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Alopecia Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Alopecia Treatment Market By Cell Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Alopecia Areata |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Androgenic Alopecia |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Traction Alopecia |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Alopecia Treatment Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Corticosteroids |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. 5AR Inhibitors |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Vasodilators |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Alopecia Treatment Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Retail Pharmacy |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospital Pharmacy |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Alopecia Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Alopecia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Cell Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Alopecia Areata |
| 9.1.2.Androgenic Alopecia |
| 9.1.3.Traction Alopecia |
| 9.1.4.Others |
| 9.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Corticosteroids |
| 9.2.2.5AR Inhibitors |
| 9.2.3.Vasodilators |
| 9.2.4.Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Retail Pharmacy |
| 9.3.2.Hospital Pharmacy |
| 9.3.3.Online Pharmacy |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Alopecia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Alopecia Areata |
| 10.1.2.Androgenic Alopecia |
| 10.1.3.Traction Alopecia |
| 10.1.4.Others |
| 10.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Corticosteroids |
| 10.2.2.5AR Inhibitors |
| 10.2.3.Vasodilators |
| 10.2.4.Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Retail Pharmacy |
| 10.3.2.Hospital Pharmacy |
| 10.3.3.Online Pharmacy |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 10.4.7. |
| 11.Asia Pacific (APAC) Alopecia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Alopecia Areata |
| 11.1.2.Androgenic Alopecia |
| 11.1.3.Traction Alopecia |
| 11.1.4.Others |
| 11.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Corticosteroids |
| 11.2.2.5AR Inhibitors |
| 11.2.3.Vasodilators |
| 11.2.4.Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Retail Pharmacy |
| 11.3.2.Hospital Pharmacy |
| 11.3.3.Online Pharmacy |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Alopecia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Alopecia Areata |
| 12.1.2.Androgenic Alopecia |
| 12.1.3.Traction Alopecia |
| 12.1.4.Others |
| 12.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Corticosteroids |
| 12.2.2.5AR Inhibitors |
| 12.2.3.Vasodilators |
| 12.2.4.Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Retail Pharmacy |
| 12.3.2.Hospital Pharmacy |
| 12.3.3.Online Pharmacy |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Alopecia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Alopecia Areata |
| 13.1.2.Androgenic Alopecia |
| 13.1.3.Traction Alopecia |
| 13.1.4.Others |
| 13.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Corticosteroids |
| 13.2.2.5AR Inhibitors |
| 13.2.3.Vasodilators |
| 13.2.4.Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Retail Pharmacy |
| 13.3.2.Hospital Pharmacy |
| 13.3.3.Online Pharmacy |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Cellmid Ltd. (Australia) |
| 14.2.2.Cipla Ltd. (India) |
| 14.2.3.Reddys Laboratories Ltd. (India) |
| 14.2.4.Johnson & Johnson Services, Inc. (U.S) |
| 14.2.5.Merck & Co., Inc. (U.S) |
| 14.2.6.Phyto Ales Group (France) |
| 14.2.7.Shiseido Co., Ltd.(Japan) |
| 14.2.8.Sun Pharmaceutical Industries Ltd. (India) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Cellmid Ltd. (Australia)
- Cipla Ltd. (India)
- Reddys Laboratories Ltd. (India)
- Johnson & Johnson Services, Inc. (U.S)
- Merck & Co., Inc. (U.S)
- Phyto Ales Group (France)
- Shiseido Co., Ltd.(Japan)
- Sun Pharmaceutical Industries Ltd. (India)
- Taisho Pharmaceutical Holdings Co., Ltd (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- The Himalaya Drug Company (India)
- Vitabiotics (U.K)